Friday 5-16-2014 Arrowhead Research Corp (ARWR) $ARWR opened at 10.94 hitting the high price of 10.98 and a day low of 10.32 with a total volume of 936,100. ARWR had a previous close of 11.00 and has been seeing an average volume of 1,355,440.
Overall Average: 56% Sell
Recent stock forum discussions about ARWR http://investorshangout.com/search?q=ARWR&...mp;yt0=Go!
Earnings Release Results, and Leadership Appointments - Analyst Notes on Halozyme, MannKind, Arrowhead, Idera and BioCryst
PR Newswire - Fri May 16, 6:00AM CDT
Today, Analysts Review released its analysts' notes regarding Halozyme Therapeutics, Inc. (NASDAQ: HALO), MannKind Corp. (NASDAQ: MNKD), Arrowhead Research Corp. (NASDAQ: ARWR), Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) and BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/2534-100free. (full story)
Downtrend Call Working As Arrowhead Research Stock Falls 40.5% (ARWR)
Comtex SmarTrend(R) - Thu May 15, 9:35AM CDT
SmarTrend identified a Downtrend for Arrowhead Research (NASDAQ:ARWR) on March 24th, 2014 at $18.54. In approximately 2 months, Arrowhead Research has returned 40.54% as of today's recent price of $11.02. (full story)
Shares of ARWR Down 45.9% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Thu May 08, 9:08AM CDT
SmarTrend identified a Downtrend for Arrowhead Research (NASDAQ:ARWR) on March 24th, 2014 at $18.54. In approximately 2 month, Arrowhead Research has returned 45.94% as of today's recent price of $10.02. (full story)
Metastatic Liver Cancer - Pipeline Review, H1 2014: 8 Companies and 8 Drugs Profiled
M2 - Thu May 08, 4:33AM CDT
Research and Markets (http://www.researchandmarkets.com/research/b7pjhn/metastatic_liver) has announced the addition of the "Metastatic Liver Cancer - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Metastatic Liver Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Liver Cancer and special features on late-stage and discontinued projects. Scope - The report provides a snapshot of the global therapeutic landscape of Metastatic Liver Cancer - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Metastatic Liver Cancer and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Metastatic Liver Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Metastatic Liver Cancer pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Involved: - Arrowhead Research Corporation - Celsion Corporation - F. Hoffmann-La Roche Ltd. - Mirna Therapeutics, Inc. - PreScience Labs, LLC - Provectus Biopharmaceuticals, Inc. - Tekmira Pharmaceuticals Corp. - Transgene Biotek Limited Drug Profiles: - RG-7686 - rose bengal sodium - MRX-34 - TKM-PLK1 - PSL-001 - doxorubicin liposomal - TBL-0404 - Peptide Drug Conjugate For Metastatic Liver Cancer For more information visit http://www.researchandmarkets.com/research/b7...atic_liver (full story)
Arrowhead to Present at Upcoming Scientific Conferences
Business Wire - Tue May 06, 3:02PM CDT
Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that it will present at multiple scientific conferences in May. (full story)
Arrowhead Reports Fiscal 2014 Second Quarter Financial Results
Business Wire - Tue May 06, 3:01PM CDT
Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced financial results for its fiscal 2014 second quarter ended March 31, 2014. The company is hosting a conference call at 4:30 p.m. EDT to discuss results. To participate in the conference call, please dial 855-215-6159 (toll free from the US) or 315-625-6887 (for international callers) and enter Conference ID 35127223. Investors may also access a live audio webcast of this conference call on the Company's website at http://www.arrowheadresearch.com/presentations. (full story)
Arrowhead to Present at Deutsche Bank 39th Annual Health Care Conference
Business Wire - Thu May 01, 6:31AM CDT
Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that Bruce Given, M.D., Chief Operating Officer, will present at the Deutsche Bank 39th Annual Health Care Conference on Thursday, May 8, 2014 at 12:50 p.m. EDT at the InterContinental hotel in Boston. (full story)
Arrowhead to Report Fiscal 2014 Second Quarter Financial Results
Business Wire - Tue Apr 29, 3:06PM CDT
Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that it will report its financial results for the fiscal 2014 second quarter ended March 31, 2014, on Tuesday, May 6, 2014, at 4:30 p.m. EDT. To participate in the conference call, please dial 855-215-6159 (toll free from the US) or 315-625-6887 (for international callers) and enter Conference ID 35127223. Investors may also access a live audio webcast of this conference call on the Company's website at http://www.arrowheadresearch.com/presentations. (full story)
Nasdaq stocks posting largest percentage decreases
AP - Mon Apr 28, 5:13PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading: (full story)
Top Gainers on the Move -- Research on Arrowhead Research, Endocyte, Ambac Financial, and ZIOPHARM Oncology
PR Newswire - Wed Apr 23, 11:40AM CDT
The trading session on Tuesday, April 22, 2014 ended on a higher note as the Dow Jones Industrial Average finished at 16,514.37, up 0.40% and the NASDAQ Composite closed at 4,161.46, up 0.97%. The S&P 500 finished the session 0.41% higher at 1,879.55. The gains were broad based as eight out of ten sectors finished on a positive note. A number of stocks saw large movements, including Arrowhead Research Corp. (NASDAQ: ARWR), Endocyte Inc. (NASDAQ: ECYT), Ambac Financial Group Inc. (NASDAQ: AMBC) and ZIOPHARM Oncology Inc. (NASDAQ: ZIOP). Free technical research on ARWR, ECYT, AMBC and ZIOP can be downloaded upon signing up at: (full story)
Arrowhead Research Shares Down 29.9% Since SmarTrend's Sell Call (ARWR)
Comtex SmarTrend(R) - Wed Apr 23, 10:57AM CDT
SmarTrend identified a Downtrend for Arrowhead Research (NASDAQ:ARWR) on March 24th, 2014 at $18.54. In approximately 1 month, Arrowhead Research has returned 29.86% as of today's recent price of $13.00. (full story)
35.3% Return Seen to Date on SmarTrend Arrowhead Research Call (ARWR)
Comtex SmarTrend(R) - Wed Apr 16, 9:35AM CDT
SmarTrend identified a Downtrend for Arrowhead Research (NASDAQ:ARWR) on March 24th, 2014 at $18.54. In approximately 3 weeks, Arrowhead Research has returned 35.34% as of today's recent price of $11.99. (full story)
Trade-Ideas: Arrowhead Research Corporation (ARWR) Is Today's "Dead Cat Bounce" Stock
at The Street - Wed Apr 16, 8:47AM CDT
Trade-Ideas LLC identified Arrowhead Research Corporation (ARWR) as a "dead cat bounce" (down big yesterday but up big today) candidate (full story)
SmarTrend Watching for Potential Rebound in Shares of Arrowhead Research After 4.87% Loss
Comtex SmarTrend(R) - Mon Apr 14, 5:45PM CDT
Arrowhead Research (NASDAQ:ARWR) traded in a range yesterday that spanned from a low of $12.32 to a high of $13.76. Yesterday, the shares fell 4.9%, which took the trading range below the 3-day low of $12.84 on volume of 3.3 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion. (full story)
Why Arrowhead Research (ARWR) Stock is Down Today
at The Street - Mon Apr 14, 2:00PM CDT
Arrowhead Research (ARWR) dipped Monday amid reports that Novartis (NVS) is closing a significant portion of its RNAi research endeavors in Boston. FierceBiotech reported the pharmaceutical giant's confirmation that ongoing problems in delivering... (full story)
Overall Average: 56% Sell
Recent stock forum discussions about ARWR http://investorshangout.com/search?q=ARWR&...mp;yt0=Go!
Earnings Release Results, and Leadership Appointments - Analyst Notes on Halozyme, MannKind, Arrowhead, Idera and BioCryst
PR Newswire - Fri May 16, 6:00AM CDT
Today, Analysts Review released its analysts' notes regarding Halozyme Therapeutics, Inc. (NASDAQ: HALO), MannKind Corp. (NASDAQ: MNKD), Arrowhead Research Corp. (NASDAQ: ARWR), Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) and BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/2534-100free. (full story)
Downtrend Call Working As Arrowhead Research Stock Falls 40.5% (ARWR)
Comtex SmarTrend(R) - Thu May 15, 9:35AM CDT
SmarTrend identified a Downtrend for Arrowhead Research (NASDAQ:ARWR) on March 24th, 2014 at $18.54. In approximately 2 months, Arrowhead Research has returned 40.54% as of today's recent price of $11.02. (full story)
Shares of ARWR Down 45.9% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Thu May 08, 9:08AM CDT
SmarTrend identified a Downtrend for Arrowhead Research (NASDAQ:ARWR) on March 24th, 2014 at $18.54. In approximately 2 month, Arrowhead Research has returned 45.94% as of today's recent price of $10.02. (full story)
Metastatic Liver Cancer - Pipeline Review, H1 2014: 8 Companies and 8 Drugs Profiled
M2 - Thu May 08, 4:33AM CDT
Research and Markets (http://www.researchandmarkets.com/research/b7pjhn/metastatic_liver) has announced the addition of the "Metastatic Liver Cancer - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Metastatic Liver Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Liver Cancer and special features on late-stage and discontinued projects. Scope - The report provides a snapshot of the global therapeutic landscape of Metastatic Liver Cancer - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Metastatic Liver Cancer and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Metastatic Liver Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Metastatic Liver Cancer pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Involved: - Arrowhead Research Corporation - Celsion Corporation - F. Hoffmann-La Roche Ltd. - Mirna Therapeutics, Inc. - PreScience Labs, LLC - Provectus Biopharmaceuticals, Inc. - Tekmira Pharmaceuticals Corp. - Transgene Biotek Limited Drug Profiles: - RG-7686 - rose bengal sodium - MRX-34 - TKM-PLK1 - PSL-001 - doxorubicin liposomal - TBL-0404 - Peptide Drug Conjugate For Metastatic Liver Cancer For more information visit http://www.researchandmarkets.com/research/b7...atic_liver (full story)
Arrowhead to Present at Upcoming Scientific Conferences
Business Wire - Tue May 06, 3:02PM CDT
Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that it will present at multiple scientific conferences in May. (full story)
Arrowhead Reports Fiscal 2014 Second Quarter Financial Results
Business Wire - Tue May 06, 3:01PM CDT
Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced financial results for its fiscal 2014 second quarter ended March 31, 2014. The company is hosting a conference call at 4:30 p.m. EDT to discuss results. To participate in the conference call, please dial 855-215-6159 (toll free from the US) or 315-625-6887 (for international callers) and enter Conference ID 35127223. Investors may also access a live audio webcast of this conference call on the Company's website at http://www.arrowheadresearch.com/presentations. (full story)
Arrowhead to Present at Deutsche Bank 39th Annual Health Care Conference
Business Wire - Thu May 01, 6:31AM CDT
Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that Bruce Given, M.D., Chief Operating Officer, will present at the Deutsche Bank 39th Annual Health Care Conference on Thursday, May 8, 2014 at 12:50 p.m. EDT at the InterContinental hotel in Boston. (full story)
Arrowhead to Report Fiscal 2014 Second Quarter Financial Results
Business Wire - Tue Apr 29, 3:06PM CDT
Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that it will report its financial results for the fiscal 2014 second quarter ended March 31, 2014, on Tuesday, May 6, 2014, at 4:30 p.m. EDT. To participate in the conference call, please dial 855-215-6159 (toll free from the US) or 315-625-6887 (for international callers) and enter Conference ID 35127223. Investors may also access a live audio webcast of this conference call on the Company's website at http://www.arrowheadresearch.com/presentations. (full story)
Nasdaq stocks posting largest percentage decreases
AP - Mon Apr 28, 5:13PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading: (full story)
Top Gainers on the Move -- Research on Arrowhead Research, Endocyte, Ambac Financial, and ZIOPHARM Oncology
PR Newswire - Wed Apr 23, 11:40AM CDT
The trading session on Tuesday, April 22, 2014 ended on a higher note as the Dow Jones Industrial Average finished at 16,514.37, up 0.40% and the NASDAQ Composite closed at 4,161.46, up 0.97%. The S&P 500 finished the session 0.41% higher at 1,879.55. The gains were broad based as eight out of ten sectors finished on a positive note. A number of stocks saw large movements, including Arrowhead Research Corp. (NASDAQ: ARWR), Endocyte Inc. (NASDAQ: ECYT), Ambac Financial Group Inc. (NASDAQ: AMBC) and ZIOPHARM Oncology Inc. (NASDAQ: ZIOP). Free technical research on ARWR, ECYT, AMBC and ZIOP can be downloaded upon signing up at: (full story)
Arrowhead Research Shares Down 29.9% Since SmarTrend's Sell Call (ARWR)
Comtex SmarTrend(R) - Wed Apr 23, 10:57AM CDT
SmarTrend identified a Downtrend for Arrowhead Research (NASDAQ:ARWR) on March 24th, 2014 at $18.54. In approximately 1 month, Arrowhead Research has returned 29.86% as of today's recent price of $13.00. (full story)
35.3% Return Seen to Date on SmarTrend Arrowhead Research Call (ARWR)
Comtex SmarTrend(R) - Wed Apr 16, 9:35AM CDT
SmarTrend identified a Downtrend for Arrowhead Research (NASDAQ:ARWR) on March 24th, 2014 at $18.54. In approximately 3 weeks, Arrowhead Research has returned 35.34% as of today's recent price of $11.99. (full story)
Trade-Ideas: Arrowhead Research Corporation (ARWR) Is Today's "Dead Cat Bounce" Stock
at The Street - Wed Apr 16, 8:47AM CDT
Trade-Ideas LLC identified Arrowhead Research Corporation (ARWR) as a "dead cat bounce" (down big yesterday but up big today) candidate (full story)
SmarTrend Watching for Potential Rebound in Shares of Arrowhead Research After 4.87% Loss
Comtex SmarTrend(R) - Mon Apr 14, 5:45PM CDT
Arrowhead Research (NASDAQ:ARWR) traded in a range yesterday that spanned from a low of $12.32 to a high of $13.76. Yesterday, the shares fell 4.9%, which took the trading range below the 3-day low of $12.84 on volume of 3.3 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion. (full story)
Why Arrowhead Research (ARWR) Stock is Down Today
at The Street - Mon Apr 14, 2:00PM CDT
Arrowhead Research (ARWR) dipped Monday amid reports that Novartis (NVS) is closing a significant portion of its RNAi research endeavors in Boston. FierceBiotech reported the pharmaceutical giant's confirmation that ongoing problems in delivering... (full story)
